The role of FGF23 in CKD-with or without Klotho

Nature Reviews Nephrology

Volumn 8, Issue 8, 2012, Pages 484-490

  Komaba, Hirotaka ^a   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CINACALCET; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; IRON SACCHARATE; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; VITAMIN D;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MINERAL METABOLISM; NONHUMAN; PARATHYROIDECTOMY; PHOSPHATURIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; BONE DISEASES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84864339688     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.116     Document Type: Review

References (80)

1. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047 (2007). (Pubitemid 350074801)
2. Imai, E. et al. Prevalence of chronic kidney disease in the Japanese general population. Clin. Exp. Nephrol. 13, 621-630 (2009).
3. Block, G. A. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208-2218 (2004). (Pubitemid 39031360)
4. Slatopolsky, E. & Delmez, J. A. Pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 11 (Suppl. 3), 130-135 (1996). (Pubitemid 26278603)
5. Komaba, H. & Fukagawa, M. FGF23-parathyroid interaction: Implications in chronic kidney disease. Kidney Int. 77, 292-298 (2010).
6. Gutiérrez, O. M. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: Updating the trade-off hypothesis. Clin. J. Am. Soc. Nephrol. 5, 1710-1716 (2010).
7. Parker, B. D. et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann. Intern. Med. 152, 640-648 (2010).
8. Seiler, S. et al. FGF 23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant. 25, 3983-3989 (2010).
9. Isakova, T. et al. for the Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432-2439 (2011).
10. Kendrick, J. et al. FGF 23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22, 1913-1922 (2011).
11. Fliser, D. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18, 2600-2608 (2007).
12. Semba, R. D. et al. Serum fibroblast growth factor 23 and risk of incident chronic kidney disease in older community-dwelling women. Clin. J. Am. Soc. Nephrol. 7, 85-91 (2012).
13. Nakano, C. et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin. J. Am. Soc. Nephrol. 7, 810-819 (2012).
14. Gutiérrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
15. Jean, G. et al. High levels of serum fibroblast growth factor (FGF) 23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 24, 2792-2796 (2009).
16. Olauson, H. et al. Relation between serum fibroblast growth factor 23 level and mortality in incident dialysis patients: Are gender and cardiovascular disease confounding the relationship? Nephrol. Dial. Transplant. 25, 3033-3038 (2010).
17. Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408 (2011).
18. Yamashita, T., Yoshioka, M. & Itoh, N. Identification of a novel fibroblast growth factor, FGF 23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277, 494-498 (2000).
19. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26, 345-348 (2000).
20. Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500-6505 (2001). (Pubitemid 32488266)
21. Benet-Pagès, A. et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35, 455-462 (2004). (Pubitemid 38953193)
22. Takeuchi, Y. et al. Venous sampling for fibroblast growth factor 23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89, 3979-3982 (2004). (Pubitemid 39071502)
23. Khosravi, A. et al. Determination of the elimination half-life of fibroblast growth factor 23. J. Clin. Endocrinol. Metab. 92, 2374-2377 (2007). (Pubitemid 46997149)
24. Shimada, T. et al. FGF 23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429-435 (2004). (Pubitemid 38787398)
25. Ben-Dov, I. Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003-4008 (2007). (Pubitemid 350224109)
26. Kurosu, H. et al. Regulation of fibroblast growth factor 23 signaling by Klotho. J. Biol. Chem. 281, 6120-6123 (2006). (Pubitemid 43847540)
27. Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774 (2006). (Pubitemid 44949607)
28. Bai, X., Dinghong, Q., Miao, D., Goltzman, D. & Karaplis, A. C. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am. J. Physiol. Endocrinol. Metab. 296, E79-E88 (2009).
29. Nakatani, T. et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 23, 433-441 (2009).
30. Weber, T. J., Liu, S., Indridason, O. S. & Quarles, L. D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18, 1227-1234 (2003). (Pubitemid 37294915)
31. Shimada, T. et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95, 578-585 (2010).
32. Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 71, 31-38 (2007). (Pubitemid 44967731)
33. Shigematsu, T. et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44, 250-256 (2004). (Pubitemid 38962552)
34. Gutierrez, O. et al. Fibroblast growth factor 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205-2215 (2005). (Pubitemid 41716454)
35. Pereira, R. C. et al. Patterns of FGF 23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45, 1161-1168 (2009).
36. Hasegawa, H. et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78, 975-980 (2010).
37. Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370-1378 (2011).
38. Ferrari, S. L., Bonjour, J. P. & Rizzoli, R. Fibroblast growth factor 23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90, 1519-1524 (2005). (Pubitemid 40464013)
39. Burnett, S. M. et al. Regulation of C terminal and intact FGF 23 by dietary phosphate in men and women. J. Bone Miner. Res. 21, 1187-1196 (2006).
40. Antoniucci, D. M., Yamashita, T. & Portale, A. A. Dietary phosphorus regulates serum fibroblast growth factor 23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91, 3144-3149 (2006). (Pubitemid 44271770)
41. Nishida, Y. et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 70, 2141-2147 (2006). (Pubitemid 44871378)
42. Ito, N. et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J. Bone Miner. Metab. 25, 419-422 (2007). (Pubitemid 350043699)
43. Oliveira, R. B. et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 5, 286-291 (2010).
44. Gonzalez-Parra, E. et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol. Dial. Transplant. 26, 2567-2571 (2011).
45. Yilmaz, M. I. et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am. J. Kidney Dis. 59, 177-185 (2012).
46. Isakova, T. et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 26, 584-591 (2011).
47. Urena Torres, P., Friedlander, G., De Vernejoul, M. C., Silve, C. & Prié, D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 73, 102-107 (2008). (Pubitemid 350273643)
48. Bhan, I. et al. Post-transplant hypophosphatemia: Tertiary hyper-phosphatoninism? Kidney Int. 70, 1486-1494 (2006).
49. Evenepoel, P., Naesens, M., Claes, K., Kuypers, D. & Vanrenterghem, Y. Tertiary hyperphosphatoninism accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am. J. Transplant. 7, 1193-1200 (2007). (Pubitemid 46643105)
50. Kestenbaum, B. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16, 520-528 (2005). (Pubitemid 41725150)
51. Menon, V. et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am. J. Kidney Dis. 46, 455-463 (2005). (Pubitemid 41208181)
52. Tonelli, M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112, 2627-2633 (2005). (Pubitemid 41532599)
53. Koh, N. et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 280, 1015-1020 (2001). (Pubitemid 32924441)
54. Fukagawa, M. & Kazama, J. J. With or without the kidney: The role of FGF23 in CKD. Nephrol. Dial. Transplant. 20, 1295-1298 (2005). (Pubitemid 41430600)
55. Kazama, J. J. et al. Pretreatment serum FGF 23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 67, 1120-1125 (2005). (Pubitemid 41623338)
56. Nakanishi, S. et al. Serum fibroblast growth factor 23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 67, 1171-1178 (2005). (Pubitemid 41623344)
57. Nishi, H. et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin. Pract. 101, c94-c99 (2005). (Pubitemid 41208897)
58. Wesseling-Perry, K. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int. 79, 112-119 (2011).
59. Hansen, D., Rasmussen, K., Pedersen, S. M., Rasmussen, L. M. & Brandi, L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol. Dial. Transplant. 27, 2263-2269 (2012).
60. Wetmore, J. B., Liu, S., Krebill, R., Menard, R. & Quarles, L. D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 5, 110-116 (2010).
61. Koizumi, M., Komaba, H., Nakanishi, S., Fujimori, A. & Fukagawa, M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 27, 784-790 (2012).
62. Sato, T. et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am. J. Kidney Dis. 44, 481-487 (2004). (Pubitemid 39164625)
63. Koiwa, F. et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 9, 336-339 (2005). (Pubitemid 41800805)
64. Shigematsu, T. & Negi, S. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF 23 level independently of calcium and PTH (COLC Study). Nephrol. Dial. Transplant. 27, 1050-1054 (2012).
65. Takeda, Y. et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am. J. Nephrol. 33, 421-426 (2011).
66. Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882-F889 (2010).
67. López, I. et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 80, 475-482 (2011).
68. Liu, S. et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17, 1305-1315 (2006). (Pubitemid 43673410)
69. Komaba, H. et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77, 232-238 (2010).
70. Kumata, C. et al. Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am. J. Nephrol. 31, 230-238 (2010).
71. Galitzer, H., Ben-Dov, I. Z., Silver, J. & Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211-218 (2010).
72. Canalejo, R. et al. FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 21, 1125-1135 (2010).
73. Hofman-Bang, J., Martuseviciene, G., Santini, M. A., Olgaard, K. & Lewin, E. Increased parathyroid expression of klotho in uremic rats. Kidney Int. 78, 1119-1127 (2010).
74. Martuseviciene, G., Hofman-Bang, J., Clausen, T., Olgaard, K. & Lewin, E. The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int. 79, 742-748 (2011).
75. Goetz, R. et al. Isolated C terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23 FGFR Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407-412 (2010).
76. Isakova, T. et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20, 388-396 (2009).
77. Wetmore, J. B. et al. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J. Clin. Endocrinol. Metab. 96, E57-E64 (2011).
78. Okuno, S. et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 18, 2613-2621 (2003). (Pubitemid 37483797)
79. Komaba, H. et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 5, 2305-2314 (2010).
80. Teng, M. et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J. Am. Soc. Nephrol. 16, 1115-1125 (2005).(Pubitemid 41710323)